Aperio Group LLC Boosts Position in Lexicon Pharmaceuticals, Inc. (LXRX)

Aperio Group LLC increased its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 49.5% in the first quarter, HoldingsChannel reports. The institutional investor owned 19,270 shares of the biopharmaceutical company’s stock after buying an additional 6,377 shares during the period. Aperio Group LLC’s holdings in Lexicon Pharmaceuticals were worth $165,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Schwab Charles Investment Management Inc. grew its holdings in shares of Lexicon Pharmaceuticals by 3.2% during the first quarter. Schwab Charles Investment Management Inc. now owns 226,635 shares of the biopharmaceutical company’s stock worth $1,943,000 after buying an additional 7,078 shares in the last quarter. State of Wisconsin Investment Board grew its holdings in shares of Lexicon Pharmaceuticals by 446.6% during the first quarter. State of Wisconsin Investment Board now owns 169,456 shares of the biopharmaceutical company’s stock worth $1,452,000 after buying an additional 138,456 shares in the last quarter. Quantitative Systematic Strategies LLC grew its holdings in shares of Lexicon Pharmaceuticals by 61.4% during the first quarter. Quantitative Systematic Strategies LLC now owns 19,171 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 7,296 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of Lexicon Pharmaceuticals by 5,444.4% during the first quarter. Victory Capital Management Inc. now owns 86,327 shares of the biopharmaceutical company’s stock worth $739,000 after buying an additional 84,770 shares in the last quarter. Finally, Virginia Retirement Systems ET AL grew its holdings in shares of Lexicon Pharmaceuticals by 45.6% during the first quarter. Virginia Retirement Systems ET AL now owns 68,300 shares of the biopharmaceutical company’s stock worth $585,000 after buying an additional 21,400 shares in the last quarter.

Get Lexicon Pharmaceuticals alerts:

In other news, VP James F. Tessmer sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, June 8th. The stock was sold at an average price of $12.91, for a total value of $129,100.00. Following the completion of the sale, the vice president now directly owns 35,643 shares of the company’s stock, valued at $460,151.13. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Public Equities L.P. Invus acquired 433,378 shares of the business’s stock in a transaction dated Wednesday, May 30th. The stock was acquired at an average cost of $9.94 per share, with a total value of $4,307,777.32. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 1,360,095 shares of company stock valued at $15,288,791. Insiders own 6.10% of the company’s stock.

A number of research firms have weighed in on LXRX. Stifel Nicolaus decreased their price target on Lexicon Pharmaceuticals from $25.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, May 4th. Zacks Investment Research upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, March 21st. Wedbush raised their price target on Lexicon Pharmaceuticals from $38.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, April 16th. BidaskClub upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, May 4th. Finally, Citigroup decreased their price target on Lexicon Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating for the company in a research note on Friday, May 4th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $24.40.

Lexicon Pharmaceuticals opened at $12.91 on Monday, Marketbeat reports. The company has a quick ratio of 2.70, a current ratio of 2.72 and a debt-to-equity ratio of 8.85. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -10.17 and a beta of 0.48. Lexicon Pharmaceuticals, Inc. has a twelve month low of $7.67 and a twelve month high of $18.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.03. The firm had revenue of $25.21 million during the quarter, compared to the consensus estimate of $25.30 million. Lexicon Pharmaceuticals had a negative return on equity of 213.32% and a negative net margin of 140.09%. The business’s revenue was up 37.8% compared to the same quarter last year. During the same period last year, the company earned ($0.33) earnings per share. research analysts predict that Lexicon Pharmaceuticals, Inc. will post -1.33 earnings per share for the current fiscal year.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).